BridgeBio is growing revenue 120% YoY with 41.5% upside to the analyst target, but it burns cash at -45% of revenue, has missed earnings in 3 of 4 quarters, depends on two products and faces insider selling.
Thesis pillars
- Hypergrowth Launch→Stable
- Cash Burn Despite Growth→Stable
- Two Product Concentration↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 24, 2026, based on the 10-K filed Feb 24, 2026
BridgeBio Pharma, Inc. (BBIO) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $70.82: Quality below floor (4.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 3.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Elevated put/call ratio: 6.33; Below-average business quality.
BridgeBio Pharma commercializes Attruby (acoramidis) for ATTR-CM in the U.S. and develops therapies for genetic diseases. Attruby generated $362.4 million in U.S. net product revenues in 2025; Beyonttra contributed $105.0 million in license revenue via Bayer (Europe) and Alexion... Read more
Sell if holding. Engine safety override at $70.82: Quality below floor (4.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 3.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Elevated put/call ratio: 6.33; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 71. Score 5.8/10, moderate confidence.
Passes 7/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 0d<=7d. Suitability: speculative.
Recent developments
updated 2026-10-29Recent Developments — BridgeBio Pharma, Inc.
Latest news
- NEWS BBIO|BridgeBio Pharma Inc|Price:79.906|Chg%:-3.634 - TradingKey — TradingKey neutral
- NEWS BBIO|BridgeBio Pharma Inc|Price:79.906|Chg%:-3.634 - tradingkey.com — tradingkey.com negative
- NEWS BBIO Reiterated by HC Wainwright & Co. -- Price Target Maintained at $100 - GuruFocus — GuruFocus positive
- NEWS BridgeBio: Attruby's Early Dominance Makes The Bull Case Hard To Ignore (NASDAQ:BBIO) - Seeking Alpha — Seeking Alpha positive
- NEWS Why BridgeBio Pharma (BBIO) Is Down 6.4% After Attruby’s Faster-Than-Expected Commercial Ramp - And What's Next - simply — simplywall.st negative
Generated 2026-10-29T13:34:02Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductAttruby and Beyonttra10-K Item 1A: 'Our business is substantially dependent on the commercial success of Attruby and Beyonttra'
Material Events(8-K, last 90d)
- 2026-05-08Item 1.01LOWBridgeBio entered an Equity Distribution Agreement with Goldman Sachs and Leerink Partners on May 7, 2026 for an at-the-market offering of up to $500 million in common stock, filed alongside a Form S-3ASR registration statement.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $70.82: Quality below floor (4.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 3.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Elevated put/call ratio: 6.33; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 71. Prior stop was $66.90. Score 5.8/10, moderate confidence.
Analyst target: $97.03 (+37.0% upside). Prior stop was $66.90. Stop-loss: $66.90.
Concentration risk — Product: Attruby and Beyonttra; Quality below floor (4.0 < 4.0).
BridgeBio Pharma, Inc. trades at a P/E of N/A (forward -315.3). TrendMatrix value score: 5.4/10. Verdict: Sell.
29 analysts cover BBIO with a consensus score of 4.1/5. Average price target: $108.
What does BridgeBio Pharma, Inc. do?BridgeBio Pharma commercializes Attruby (acoramidis) for ATTR-CM in the U.S. and develops therapies for genetic...
BridgeBio Pharma commercializes Attruby (acoramidis) for ATTR-CM in the U.S. and develops therapies for genetic diseases. Attruby generated $362.4 million in U.S. net product revenues in 2025; Beyonttra contributed $105.0 million in license revenue via Bayer (Europe) and Alexion (Japan). Three Phase 3 programs—infigratinib, BBP-418, and encaleret—each reported positive data in 2025-2026 with NDA submissions planned for 2026.